These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 8233291)

  • 1. Treatment with tamoxifen and progestins for metastatic breast cancer in postmenopausal women: a quantitative review of published randomized clinical trials.
    Parazzini F; Colli E; Scatigna M; Tozzi L
    Oncology; 1993; 50(6):483-9. PubMed ID: 8233291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group.
    Byrne MJ; Gebski V; Forbes J; Tattersall MH; Simes RJ; Coates AS; Dewar J; Lunn M; Flower C; Gill PG; Stewart J
    J Clin Oncol; 1997 Sep; 15(9):3141-8. PubMed ID: 9294477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral high-dose medroxyprogesterone acetate versus tamoxifen. A randomized crossover trial in postmenopausal patients with advanced breast cancer.
    van Veelen H; Willemse PH; Tjabbes T; Schweitzer MJ; Sleijfer DT
    Cancer; 1986 Jul; 58(1):7-13. PubMed ID: 2939943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Progestational agents and bone metastasis in breast cancer].
    Leriche N; Bonneterre J
    Bull Cancer; 1997 Sep; 84(9):891-4. PubMed ID: 9435812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis.
    Peethambaram PP; Ingle JN; Suman VJ; Hartmann LC; Loprinzi CL
    Breast Cancer Res Treat; 1999 Mar; 54(2):117-22. PubMed ID: 10424402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study.
    Muss HB; Case LD; Atkins JN; Bearden JD; Cooper MR; Cruz JM; Jackson DV; O'Rourke MA; Pavy MD; Powell BL
    J Clin Oncol; 1994 Aug; 12(8):1630-8. PubMed ID: 8040675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer.
    Hayes DF; Van Zyl JA; Hacking A; Goedhals L; Bezwoda WR; Mailliard JA; Jones SE; Vogel CL; Berris RF; Shemano I
    J Clin Oncol; 1995 Oct; 13(10):2556-66. PubMed ID: 7595707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer.
    Gill PG; Gebski V; Snyder R; Burns I; Levi J; Byrne M; Coates A
    Ann Oncol; 1993 Nov; 4(9):741-4. PubMed ID: 8280654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Results of tamoxifen-medroxyprogesterone acetate sequential therapy in 22 patients with recurrent breast cancer].
    Noguchi S; Yamamoto H; Inaii H; Koyama H
    Gan To Kagaku Ryoho; 1989 Nov; 16(11):3555-8. PubMed ID: 2530936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.
    Pritchard KI; Shepherd LE; Chapman JA; Norris BD; Cantin J; Goss PE; Dent SF; Walde D; Vandenberg TA; Findlay B; O'Reilly SE; Wilson CF; Han L; Piura E; Whelan TJ; Pollak MN
    J Clin Oncol; 2011 Oct; 29(29):3869-76. PubMed ID: 21911723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
    Buzdar A; Jonat W; Howell A; Jones SE; Blomqvist C; Vogel CL; Eiermann W; Wolter JM; Azab M; Webster A; Plourde PV
    J Clin Oncol; 1996 Jul; 14(7):2000-11. PubMed ID: 8683230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.
    Kaufmann M; Bajetta E; Dirix LY; Fein LE; Jones SE; Zilembo N; Dugardyn JL; Nasurdi C; Mennel RG; Cervek J; Fowst C; Polli A; di Salle E; Arkhipov A; Piscitelli G; Miller LL; Massimini G
    J Clin Oncol; 2000 Apr; 18(7):1399-411. PubMed ID: 10735887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
    Bago-Horvath Z; Rudas M; Dubsky P; Jakesz R; Singer CF; Kemmerling R; Greil R; Jelen A; Böhm G; Jasarevic Z; Haid A; Gruber C; Pöstlberger S; Filipits M; Gnant M;
    Clin Cancer Res; 2011 Dec; 17(24):7828-34. PubMed ID: 21998336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: A randomized trial of the International Collaborative Cancer Group.
    Wils JA; Bliss JM; Marty M; Coombes G; Fontaine C; Morvan F; Olmos T; Pérez-López FR; Vassilopoulos P; Woods E; Coombes RC
    J Clin Oncol; 1999 Jul; 17(7):1988-98. PubMed ID: 10561249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
    Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
    Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormonal treatment of advanced breast cancer. A randomized trial of tamoxifen versus nandrolone decanoate.
    Kellokumpu-Lehtinen P; Huovinen R; Johansson R
    Cancer; 1987 Nov; 60(10):2376-81. PubMed ID: 3664426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effectiveness of combination hormonal therapies in advanced or recurrent breast cancer--a randomized trial of tamoxifen (TAM), medroxyprogesterone acetate (MPA), their simultaneous combination, and an alternating sequential combination of TAM plus MPA].
    Sonoo H; Senoo T; Nishiki M; Morimoto T; Takashima S
    Gan To Kagaku Ryoho; 1996 Mar; 23(4):447-54. PubMed ID: 8678496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases.
    Howell A; Robertson JF; Vergote I
    Breast Cancer Res Treat; 2003 Dec; 82(3):215-22. PubMed ID: 14703069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential treatment of metastatic breast cancer with tamoxifen after megestrol acetate therapy and vice versa (a retrospective study).
    Alexieva-Figusch J; Van Putten WL; van Gilse HA; Blonk-vd Wijst J; Klijn JG
    Med Oncol Tumor Pharmacother; 1985; 2(2):69-75. PubMed ID: 4058078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52.
    Ingle JN; Suman VJ; Mailliard JA; Kugler JW; Krook JE; Michalak JC; Pisansky TM; Wold LE; Donohue JH; Goetz MP; Perez EA
    Breast Cancer Res Treat; 2006 Jul; 98(2):217-22. PubMed ID: 16538529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.